Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The European launch represents a significant milestone for Regentis, as the product is already CE Mark-approved, allowing commercial sale in the European Economic Area.
For business and technology leaders, this development highlights the growing trend of regenerative medicine solutions that offer off-the-shelf, single-step procedures, potentially reducing surgery time and improving patient outcomes. The training program underscores the importance of physician education in adopting new medical technologies, a factor that can influence market penetration and return on investment for stakeholders.
The full press release is available at https://ibn.fm/QOWWK. Additional information about the company and its forward-looking statements can be found in its filings with the SEC, as detailed in the disclaimer.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The company’s lead product GelrinC represents a potential paradigm shift in knee cartilage repair, offering a synthetic alternative to traditional methods such as microfracture or cell-based therapies.
The implications of this launch are far-reaching: if successful, GelrinC could become a standard treatment for knee cartilage lesions, reducing the need for more invasive surgeries and accelerating recovery times. For investors, the European commercial rollout is a critical test of the company’s ability to execute on its go-to-market strategy and could influence future regulatory pathways in the U.S. and other regions.
